


NUCLEAR MEDICINE

A CASE-BASED APPROACH



Editor-in-Chief
Munir Ghesani

Section Editors
Nasrin Ghesani
E Gordon DePuey
Amir Kashefi
Yi Chen Zhang

Foreword
Satoshi Minoshima



Contents

Section 1: General Nuclear Medicine

Nasrin Ghesani, Yi Chen Zhang, Munir Ghesani

Cases

	3	
Case 1: Assessment of Osseous Metastatic Disease in Thyroid Cancer	3	
Case 2: Evaluation of Hydronephrosis	5	
Case 3: Assessment of Gastrointestinal (GI) Bleeding Site	7	
Case 4: Assessment of Postrenal Transplant Complications	8	
Case 5: Assessment of Bilateral Breast Uptake in Gallium Scan	9	
Case 6: Assessment of Neuroendocrine Malignancies	11	
Case 7: Assessment of Liver and Spleen using TC-99M Sulfur Colloid	13	
Case 8: Assessment of Percutaneous Transhepatic Cholangiography Complications	15	
Case 9: Assessment of Traumatic Biliary Injury	17	
Case 10: Assessment of Periprosthetic Infection	19	
Case 11: Assessment of Hyperthyroidism	20	
Case 12: Assessment of New Hearing Loss	21	
Case 13: Assessment of Osseous Metastasis	22	
Case 14: Assessment of Parotid Gland Swelling	23	
Case 15: Assessment of Hepatopulmonary Syndrome	24	
Case 16: Assessment of Osseous Metastatic Disease	25	
Case 17: Assessment of Osteomyelitis	27	
Case 18: Assessment of Suspected Acute Pyelonephritis	28	
Case 19: Assessment of Rising TG Levels Status Postradioiodine Ablation	29	
Case 20: Evaluation of Gastrointestinal Hemorrhage	31	
Case 21: Assessment of Metabolic Bone Disease	32	
Case 22: Assessment of Chronic Hydronephrosis	34	
Case 23: Assessment for Suspected Delayed Gastric Emptying	36	
Case 24: Assessment of Low Back Pain in a Young Patient	37	
Case 25: Evaluation of Abdominal Pain Following Renal Transplantation	38	
Case 26: Assessment of Right Upper Quadrant Pain	40	
Case 27: Assessment of Renal Ectopia and Associated Complications	41	
Case 28: Assessment of Shortness of Breath	42	
Case 29: Assessment of Diffuse Skeletal Metastases	43	
Case 30: Assessment of Uncontrolled Hypertension	44	
Case 31: Evaluation of Brain Death	45	
Case 32: Assessment of Delayed Visualization of Gallbladder	47	
Case 33: Assessment of Chronic Urinary Obstruction	49	
Case 34: Assessment of Diffuse Renal Uptake on Bone Scan	50	
Case 35: Assessment of Hypercalcemia and Hyperparathyroidism	51	
Case 36: Assessment of Back Pain	52	
Case 37: Assessment of Hyperparathyroidism	53	
Case 38: Assessment of Intracranial Mass Lesion in the Setting of Human Immunodeficiency Virus (HIV)	54	
Case 39: Assessment of Hip Pain	56	
Case 40: Assessment for Metastatic Neuroendocrine Neoplasm	58	
Case 41: Assessment of Ventriculoperitoneal (VP) Shunt Patency	60	
Case 42: Evaluation of Solitary Cold Thyroid Nodule	62	
Case 43: Assessment of SSTR Positive Tumors	63	
Case 44: Assessment of Biliary Obstruction in Neonates	64	
Case 45: Assessment of Lytic Bony Lesions	65	
Case 46: Assessment of Thyroiditis	66	
Case 47: Assessment of Infection/Inflammation with WBC Scan	67	
Case 48A: Evaluation of Osteomyelitis	68	
Case 48B: Evaluation of Osteomyelitis	69	
Case 49: Assessment of Thyroid Cancer Metastases	70	

- Case 50: Evaluation of Hyperthyroidism 71
 Case 51: Evaluation of Renal Anomalies 72
 Case 52: Evaluation of Renal Uptake on Gallium Scan 74

- Case 53: Assessment of Cardiac Ejection Fraction 75
 Case 54: Evaluation of Liver Metastases 77
 Case 55: Assessment of Multigated Equilibrium
 Angiocardigraphy (MUGA) Scan Artifacts 79

Section 2: Nuclear Cardiology

E Gordon DePuey, Munir Ghesani

Introductory Cases

83

- Case 1: Normal Female 83
 Case 2: Normal Male; Nonvisualization of Gallbladder (GB) Due to Prior Cholecystectomy 84
 Case 3: Inadequate Resting Tetrofosmin TAG 85
 Case 4: Short Septum 86
 Case 5: Prominent Anteroseptal Right Ventricle Insertion Site 87
 Case 6: Apical Physiologic Thinning 88
 Case 7: Marked Anterior Breast Attenuation Artifact 89
 Case 8: Inferolateral Breast Artifact 90
 Case 9: Moderate Diaphragmatic Attenuation 91
 Case 10: Subdiaphragmatic Scatter 92
 Case 11: Severe Inferolateral Scar; Left Ventricular Ejection Fraction (LVEF) = 32% 93
 Case 12: Scar Basal Half Inferior Wall 94
 Case 13: Inferoapical Scar; LVEF = 50% 95
 Case 14: LAD Ischemia 96
 Case 15: Marked Inferoapical Ischemia 97
 Case 16: Increased Septal Uptake Due to Left Ventricular Hypertrophy (LVH) (S/P AVR) 98
 Case 17: Hypertrophic Cardiomyopathy 99
 Case 18: Rest/Delayed Thallium; Inferior Resting Ischemia 100
 Case 19: Rest/Delayed Thallium; Scar without Ischemia 101
 Case 20: MUGA, Decline in LVEF Postchemotherapy 102

Intermediate Cases

103

- Case 1: Anterior, Apical, and Inferior Scar 103
 Case 2: D1 and LCX Ischemia 104
 Case 3: Apical and Inferolateral Ischemia; Multivessel Disease 105
 Case 4: LAD and RCA Ischemia; Transient Ischemic Dilatation (TID) 106

- Case 5: Anterior and Inferolateral Ischemia; TID, Consistent with Multivessel Disease 107
 Case 6: Apical Ischemia and Basal Inferior Ischemia 108
 Case 7: Extensive Lateral Scar with Moderate Peri-Infarct Ischemia at Anterolateral Border; Mild TID 109
 Case 8: Anterior Ischemia; Lateral Scar + Ischemia 110
 Case 9: Anterior Ischemia with Marked Post-Stress Stunning 111
 Case 10: Left Ventricular Aneurysm with Slight Peri-Infarct Ischemia 112
 Case 11: Pulmonary Hypertension with Right Ventricular (RV) Hypertrophy and Hypokinesis (Rest Only) 113
 Case 12: Permanent Pacemaker with Apical Fixed Defect and Dyskinesis 114
 Case 13: Apical Hypertrophy 115
 Case 14: Status Post Left Mastectomy; Normal Female 116
 Case 15: Shifting Breast Attenuation Artifact; Entire Scan Repeated 117
 Case 16: Left Breast Cancer; Anterior and Lateral Ischemia with Moderate TID 119
 Case 17: Absent Gallbladder Status Post Cholecystectomy; Splenomegaly (CLL); Mild Ischemia Basal Half of the Anterior Wall (No Functional Images) 120
 Case 18: Upper Mediastinal Neoplasm; Normal Myocardial Perfusion 121
 Case 19: Granulomatous Lung Disease (Rest Only); Normal Myocardial Perfusion 122
 Case 20: Hiatal Hernia; Normal Myocardial Perfusion 123

Advanced Cases

124

- Case 1: Inferolateral Breast Attenuation Artifact; Diffuse Nonischemic Cardiomyopathy 124

- Case 2: D-Shaped Left Ventricle; Dilated, Hypokinetic Right Ventricle; Pulmonary Hypertension Documented by Echocardiography 125
- Case 3: Mild Reversible Apical Defect with Moderate TID (1.25); Catheterization Demonstrated Multivessel Disease Consistent with "Balanced Ischemia" 126
- Case 4: Multiple Axillary Nodes from Breast Cancer; Normal Perfusion Scan 127
- Case 5: Pericardial Effusion with Septal Akinesis; Multivessel Ischemia 128
- Case 6: Reverse TID Due to High Post-Stress Heart Rate 129
- Case 7: Non-Injected Stress Dose 130
- Case 8: Normal Scan, Goiter 131
- Case 9: Three-Vessel Ischemia 132
- Case 10: Severe Anterior and Septal Scar, Increased L/H Ratio, Left Pleural Effusion 133
- Case 11: Herniated Bowel; Normal Myocardial Perfusion 134

Section 3: PET/CT

Amir Kashafi, Munir Ghesani

Chest Cases

137

- Case 1: Detection of Distant Metastases in Esophageal Cancer with Radiographically Operable Disease 137
- Case 2: Assessment of Recurrence of Pulmonary Malignancy 139
- Case 3: Incidental Cancer while Staging New Pulmonary Malignancy 140
- Case 4: Monitoring Response to Lung Cancer Therapy 142
- Case 5: Characterization of a Suspicious Pulmonary Nodule 143
- Case 6: Initial Staging of Pathologically Proven Pulmonary Malignancy 144
- Case 7: Breast Cancer Evaluation and Response to Therapy 146
- Case 8: Incidental Lung Cancer while Staging another Malignancy 148
- Case 9: Initial Staging of Breast Cancer 149
- Case 10: Restaging of Esophageal Cancer after Chemoradiation Therapy 150
- Case 11: Potentially Resectable Esophageal Cancer with No Distant Metastases 152
- Case 12: Resolving Equivocal Breast Findings on Anatomical Imaging 153
- Case 13: Benign Etiology with Similar appearance to Cancer 154
- Case 14: Incidental Breast Cancer During Surveillance of other Malignancies 155
- Case 15: Discrimination of Post-Radiotherapy Esophageal Tumor Mass 156

- Case 16: Complementary Role of Bone Scan and Positron Emission Tomography/Computed Tomography (PET/CT) findings in Breast Cancer 157
- Case 17: Physiologic Ovarian Activity 159
- Case 18: Initial Staging of Lymphoma 161
- Case 19: Evaluation of Response to Lymphoma Therapy 162
- Case 20: Lymphoma with Splenic Involvement 164
- Case 21: Thymic Rebound 165
- Case 22: Lymphomatous Involvement of Bone Marrow 166
- Case 23: Muscular Involvement of Lymphoma 168
- Case 24: Prognostic Value of ^{18}F Fluorodeoxyglucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) after a Single Cycle of Chemotherapy 169
- Case 25: Recurrent Malignant Melanoma 171
- Case 26: Adrenal Metastasis 172
- Case 27: Pleomorphic Sarcoma 173
- Case 28: Benign Muscle Activity 174
- Case 29: Sentinel Lymph Node Identification from Dose Extravasation 176

Abdomen and Pelvis Cases

177

- Case 1: Colorectal Cancer found During Staging of another Primary Site 177
- Case 2: Local Recurrence at Anastomotic Site 179
- Case 3: Colon Cancer Postsurgical Changes at Anastomotic Site 180
- Case 4: Peritoneal Carcinomatosis 181

Case 5: Response to Therapy 183

Case 6: Positive Relapse with Negative CEA 185

Case 7: Negative Finding with Positive CEA 186

Case 8: Colorectal with Hepatic Metastasis 188

Case 9: Cervical Cancer with Metastasis 190

Case 10: Cervical Cancer with Response to Therapy 192

Case 11: Ovarian Cancer Spread 194

Case 12: Ovarian Cancer with Poor Response to Therapy 197

Case 13: Menses 199

Case 14: Endometrial Carcinoma with Response to Treatment 201

Case 15: Endometrial Cancer—Initial Evaluation 203

Case 16: Uterine Leiomyoma 205

Case 17: Large Uterine Leiomyoma 208

Head and Neck Cases 209

Case 1: Ocular Melanoma 209

Case 2: Melanoma with Distant Metastases 211

Case 3: PET/CT of Epilepsy 213

Case 4: FDG PET of Temporal Lobe Epilepsy 216

Case 5: FDG PET of Alzheimer’s Disease 217

Case 6: PET FDG of Frontal Temporal Dementia 219

Case 7: PET FDG of Lewy Body Dementia 220

Case 8: ¹⁸F-AV45 PET 221

Case 9: FDG PET with Mild Cognitive Impairment 223

Case 10: FDG PET/CT and Glioblastoma Multiformes 224

Case 11: FDG PET of Brain Metastasis 227

Case 12: FDG PET False Negative for Glioblastoma 229

Case 13: FDG PET/CT with Brown Fat Activity Versus Tumor 230

Non-FDG PET/CT Cases 233

Case 1A: Assessment of Neuroendocrine Tumors (NETs) 233

Case 1B: Assessment of Neuroendocrine Tumors (NETs) 234

Case 2: Assessment of Prostate Cancer 236

Case 3: Assessment of Breast Cancer 238

Case 4: Assessment of Rectal Adenocarcinoma Response to Therapy 240

Case 5: Staging of Rectal Adenocarcinoma 241

Case 6: Assessment of Alzheimer’s Disease 242

Case 7: Assessment of Bone Metastasis 243

Case 8: Assessment of Biologic Therapy Response in Rheumatoid Arthritis 245

Case 9: Assessment of Early Response to Neoadjuvant Chemotherapy (NAC) in Breast Cancer 246

Index 249

Section 3

PET/CT

Amir Kashfi, Munir Ghesani

JAYPEE BROTHERS

Chest Cases

CASE 1: DETECTION OF DISTANT METASTASES IN ESOPHAGEAL CANCER WITH RADIOGRAPHICALLY OPERABLE DISEASE

Brief History

A 51-year-old male with adenocarcinoma of the gastroesophageal junction underwent neoadjuvant chemoradiation therapy prior to surgical resection. Positron emission tomography/computed tomography (PET/CT) imaging was then pursued for surveillance of response to therapy and preoperative restaging.

Findings

Findings are shown in Figures 1 to 3.

Due to evolution of distant metastatic disease, the patient was no longer a surgical candidate and continued on to pursue a more aggressive chemotherapy regimen.

Main Teaching Point

- Positron emission tomography imaging is a powerful adjunct to anatomical modalities in identifying metastatic disease, especially when little anatomic correlation is seen.







Fig. 1: Maximum intensity projection whole body image demonstrates two intense foci of radiotracer accumulation projecting over the right upper chest.



Figs. 2A and B: PET/CT images demonstrate significant interval improvement in both size and metabolic activity of the primary tumor as well as associated gastric thickening, indicating a favorable response to chemoradiation therapy. (A) Baseline study prior to radiation therapy; (B) Postradiation therapy.



Figs. 3A and B: A new focus of ^{18}F fluorodeoxyglucose (FDG) accumulation is identified within the right posterior paraspinal musculature, which is highly concerning for metastasis. Additionally, a new hypermetabolic lytic rib lesion is observed that represents osseous metastasis with high certainty. (A) Paraspinal muscular metastasis; (B) Rib metastasis.

JAYPEE BRO

CASE 2: ASSESSMENT OF RECURRENCE OF PULMONARY MALIGNANCY

Brief History

A 69-year-old female with stage IA squamous cell carcinoma of the right lower lung lobe, status post video-assisted thoracoscopic resection, was found to have two new right upper lobe pulmonary nodules by surveillance computed tomography (CT). She subsequently underwent positron emission tomography (PET/CT) imaging as scintigraphic assessment of these lesions and for restaging of her primary disease.

Findings

Findings are shown in Figures 1 to 3.

Two pulmonary nodules are identified within the right upper lobe. The larger nodule measures 0.8 cm and has SUV maximum of 3.5 g/mL, which is highly suspicious for recurrent metastatic disease. The smaller 0.4 cm nodule demonstrates no visibly elevated radiotracer accumulation, but is below threshold for reliable characterization by PET imaging.

Main Teaching Points

- Approximately 25% of patients treated for stage IA non-small cell lung cancer can develop recurrence of disease.

- Lesions less than 0.8 cm are too small to fully characterize by PET imaging and cannot be excluded as malignancy even when demonstrating background metabolic activity.




Fig. 1: Maximum intensity projection whole body image demonstrates abnormal foci of radiotracer activity projecting over the right chest and axilla.




Fig. 2: The largest 0.8 cm nodule is identified in the posterior right upper lobe.




Fig. 3: Low-grade hypermetabolic lymphadenopathy is observed within the mediastinum and right axilla.

CASE 3: INCIDENTAL CANCER WHILE STAGING NEW PULMONARY MALIGNANCY

Brief History

A 74-year-old female with a history of pulmonary large cell neuroendocrine tumor, status post left upper lobectomy, was recently diagnosed with a new right upper lobe pulmonary squamous cell carcinoma. She underwent ^{18}F fluorodeoxyglucose (FDG) positron emission

tomography/computed tomography (PET/CT) for initial staging of her disease.

Findings

Findings are shown in Figures 1 to 4.

Main Teaching Point

- Adrenal glucose metabolism greater than that of liver is worrisome for malignant involvement of either primary or metastatic nature.




Fig. 1: Maximum intensity projection whole body image demonstrates the known right upper lobe squamous cell carcinoma. Additionally, focally increased radiotracer activity is noted within the right pelvis.






Fig. 2: A hypermetabolic right upper lobe nodule correlates to the biopsy-proven squamous cell carcinoma.



Figs. 3A and B: A large, variably hypermetabolic, mixed solid-cystic ovoid mass is identified in the right pelvis. The right ovary is not visualized and the mass directly abuts the cecum. Histologic origin could either be gastrointestinal or ovarian. (A) The inferior and solid portion of the mass is adjacent to the cecum. (B) Superiorly, a cystic component is seen with decreased radiotracer activity centrally and a hypermetabolic rim.




Fig. 4: Hypermetabolic fullness of the left adrenal gland demonstrates FDG avidity greater than normal adjacent liver parenchyma, which raises concern for malignant involvement.

CASE 4: MONITORING RESPONSE TO LUNG CANCER THERAPY

Brief History


A 67-year-old male with a history of laryngeal cancer was incidentally found to have lung cancer by baseline positron emission tomography/computed tomography (PET/CT) evaluation. He subsequently underwent definitive stereotactic body radiation therapy and required reimaging for evaluation of response.

Findings

Findings are shown in Figures 1A and B.

Main Teaching Points

- Radiotherapy-treated pulmonary masses can persist as scarred parenchymal lesions.
- Comparison of ^{18}F fluorodeoxyglucose (FDG) uptake of a treated pulmonary mass to adjacent or contralateral background lung activity can help to determine if it has been adequately treated.



Figs. 1A and B: Interval decrease in metabolic activity in the left upper lobe pulmonary mass is appreciated. The lesion was originally a spiculated soft tissue density, but developed a more scarred, fibrotic appearance following radiation therapy. Visually, the metabolic activity has noticeably decreased, and the standard uptake value (SUV) maximum measurement has fallen from 5.6 g/mL to 1.8 g/mL. Adjacent background lung activity has a SUV maximum of 1.6 g/mL. (A) Baseline appearance prior to treatment; (B) Post-radiotherapy.

CASE 5: CHARACTERIZATION OF A SUSPICIOUS PULMONARY NODULE

Brief History

A 65-year-old female presented with computed tomography (CT) evidence of multiple pulmonary nodules, one of which had increased in size with a mildly spiculated appearance. She required ^{18}F fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT imaging to evaluate the functional status of this lesion.

Findings

Findings are shown in Figures 1 and 2.

Main Teaching Points

- Positron emission tomography is a useful tool to assess the metabolic activity of a newly discovered lesion, especially when limited prior imaging is available.
- Pulmonary nodules on the border of PET resolution (0.8–1.0 cm) that demonstrate background activity favor benign etiology, but should still be followed with repeat imaging in 2–3 months.





Fig. 1: Initial chest CT demonstrates an 8 mm pulmonary nodule within the lingual.



Figs. 2A and B: By PET/CT, the lesion of question demonstrates no abnormal FDG accumulation; however, the size of this lesion is on the border of reliable detection by PET resolution and should be followed with future imaging.

CASE 6: INITIAL STAGING OF PATHOLOGICALLY PROVEN PULMONARY MALIGNANCY

Brief History

A 65-year-old female presented with recently diagnosed pulmonary adenocarcinoma and required ^{18}F fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) imaging for initial staging of her disease.

Findings

Findings are shown in Figures 1 to 6.

Main Teaching Points

- Tumoral encroachment on the spinal canal is an urgent finding, and the patient should be assessed clinically for neurologic impingement.

- Positron emission tomography/computed tomography can be used to identify hypermetabolic biopsy targets to help establish metastatic pathology.




Fig. 1: Maximum intensity projection whole body image demonstrates extensive hypermetabolic metastases projecting of the right chest, right neck, and central abdomen.




Fig. 2: A large hypermetabolic right upper lobe pulmonary mass is identified.




Fig. 3: Extensive conglomerate lymphadenopathy is seen throughout nearly all nodal stations of the mediastinum and neck.




Fig. 4: Thickening of hypermetabolic right lateral paraspinous musculature is seen with direct extension between the C1/C2 interface with effacement of the thecal sac. No osseous destruction was appreciated at this location.




Fig. 5: Bulky retroperitoneal hypermetabolic lymphadenopathy represents significant metastatic spread inferior to the diaphragm.




Fig. 6: A hypermetabolic left-sided retroperitoneal lymph node is identified that would be particularly amenable to image-guided biopsy, if clinically indicated.

CASE 7: BREAST CANCER EVALUATION AND RESPONSE TO THERAPY

Brief History


A 64-year-old female with stage IIIA breast cancer was treated with modified radical mastectomy, reconstruction, and adjuvant chemotherapy with good clinical response. She was without evidence of recurrent disease for over 10 years until she presented with cardiac chest pain and computed tomography (CT) imaging revealed incidental mediastinal lymphadenopathy. Subsequent ^{18}F fluorodeoxyglucose (FDG) positron emission tomography (PET/CT) confirmed abnormal hypermetabolism, and lymph node biopsy was consistent with recurrence of breast primary malignancy. She was initiated on chemotherapy and underwent repeat PET/CT imaging to evaluate response to treatment.

Findings


Findings are shown in Figures 1 to 4.

Main Teaching Points


- Direct comparison of Standard Uptake Value (SUV) maximum measurements for select index lesions can be used to assess interval response to therapy.
- Stable or improving metabolic activity with no newly identified lesions indicates favorable response to therapy.




Figs. 1A and B: Maximum intensity projection whole body images demonstrate small subtle radiotracer-avid mediastinal lymph nodes. (A) The anterior view shows lymph nodes projecting over the central mediastinum. (B) The lateral view shows the most intense lesion is within the substernal anterior mediastinum.



Figs. 2A and B: A hypermetabolic retrosternal anterior mediastinal lymph node has decreased in size from 1.1 x 1.5 cm to 0.8 x 1.1 cm. The SUV maximum measurement has also decreased from 4.7 g/mL to 2.4 g/mL. (A) Baseline study prior to chemotherapy. (B) Post-chemotherapy.



Figs. 3A and B: A persistent hypermetabolic lymph node in the left perihilar region is stable in both size and metabolic activity. (A) Baseline study prior to chemotherapy. (B) Post-chemotherapy.



Figs. 4A and B: An aortopulmonary window hypermetabolic lymph nodes has decreased in standard uptake value (SUV) maximum measurement from 3.5 g/mL to 2.5 g/mL and visually appears slightly less intense. Anterior to this lesion is a hypermetabolic prevascular lymph node that has remained stable. (A) Baseline study prior to chemotherapy. (B) Post-chemotherapy.

NUCLEAR MEDICINE

A CASE-BASED APPROACH

This book is designed to meet the learning needs of the residents in training as well as to serve as a resourceful case-based review for imaging professionals. It provides pertinent, up-to-date information on general nuclear medicine, nuclear cardiology and PET-CT in a popular case-based format. In order to stimulate gradual learning, each section is divided in three progressive phases by providing increasing complexities of the cases from introductory to intermediate to difficult levels.

Munir Ghesani MD FACNM has been practicing clinical nuclear medicine for the past two decades, USA. He has served as Associate Director of the Radiology Residency Program at St Luke's-Roosevelt Hospital Center in New York City, USA for more than 10 years and is currently serving as Program Director of PET-CT Fellowship at NYU, Langone Medical Center, New York, USA. He has been an educator for nuclear medicine technology students and medical students for 20 years. He has held various leadership positions, including President of a hospital-based radiology practice and CEO of a private practice radiology group. In the past, he has received the "Teacher of the Year" award given by diagnostic radiology residents. Outside of the institutional responsibilities, Dr Ghesani has held leadership positions in several organizations, including current Chairman of the Government Relations Committee (SNMMI), current co-chairman of the Membership Task Force (SNMMI), current Vice-Chair (ABNM) and former President (ACNM).



Nasrin Ghesani MD completed her medical school training at Government Medical School, Surat, India and completed residency training in nuclear medicine at Hahnemann University Hospital and at Hospital of University of Pennsylvania, Philadelphia, USA. After completing residency training, she joined New Jersey Medical School. She is currently an Associate Professor in Radiology and Medicine at Rutgers New Jersey Medical School, Newark, New Jersey, USA, and Director of Nuclear Medicine at University Hospital, Newark, New Jersey, USA. She has received several research grants from state and national foundations to pursue research in nuclear medicine and molecular imaging and has published her work in peer-reviewed journals.



E Gordon DePuey MD completed his medical school training at Baylor College of Medicine, Houston, Texas, USA and completed residencies in Internal Medicine and Nuclear Medicine and Fellowship in Nuclear Cardiology also at Baylor College of Medicine. He is Board Certified by the ABIM, ABNM, and the CBNC and a fellow of the ACC. After holding faculty positions at Baylor, Emory and Columbia Universities, he is now a Clinical Professor of Radiology at Icahn School of Medicine at Mount Sinai and Director of Nuclear Medicine at Mount Sinai St. Luke's-Roosevelt Hospital in New York City, New York, USA. He is a Past-President of the Cardiovascular Council of the SNM, presently serves on the Board of Directors of the Cardiovascular Council of the SNMMI, served for five years as Chairman of the Quality Assurance Committee of ASNC, served as Vice-President and President of ASNC, and is now Immediate Past President of ASNC. He has authored over 150 publications in peer-reviewed journals, many book chapters, and two textbooks in Nuclear Cardiology. His current major focus of research involves Nuclear Cardiology image processing software to streamline imaging and improve image quality and diagnostic accuracy.



Amir Kashefi MD graduated from Tehran University of Medical Sciences, Tehran, Iran and moved to the United States to pursue a career in radiology. He completed his chief residency in Nuclear Medicine and PET-CT fellowship at UC Davis Medical Center in Sacramento, California, USA. He subsequently went on to a radiology residency at Harlem Hospital, an affiliate of Columbia Medical Center. He has recently joined Massachusetts General Hospital, Boston, MA, USA, where he is focusing on abdominal imaging and interventional radiology as a Fellow. He has written two chapters in "Fundamentals of Diagnostic Radiology, 4th edition" including a chapter on molecular imaging. He has considerable research experience in molecular imaging and the results of his studies have been published in peer-reviewed journals. In addition, he has presented his research at many national and international medical conferences.



Yi Chen Zhang MD completed her Bachelor of Arts degree in Biochemistry at Harvard University, Cambridge, Massachusetts, USA, and her medical school training at Albert Einstein College of Medicine, New York, USA. She is currently completing her chief residency in Radiology and her residency in Nuclear Medicine at the Mount Sinai St Luke's-Roosevelt Hospital System in New York, NY, USA. She has published eight peer-reviewed research articles ranging from benchwork immunology research to neuroradiology. Previously, she has worked for the World Health Organization, MIT Lincoln Labs, and Center for Blood Research at Harvard Medical School, Boston, Massachusetts, USA.



Available at all medical bookstores
or buy online at www.jaypeebrothers.com

 **JAYPEE BROTHERS**
Medical Publishers (P) Ltd.
www.jaypeebrothers.com

Join us on [facebook.com/JaypeeMedicalPublishers](https://www.facebook.com/JaypeeMedicalPublishers)

Shelving
Recommendation
MEDICINE

